Literature DB >> 3096499

Depletion of striatal beta-phenylethylamine following dopamine but not 5-HT denervation.

A J Greenshaw, A V Juorio, T V Nguyen.   

Abstract

The effects of lesions of the substantia nigra (electrolytic 2 mA 10 sec, or 6-OHDA 2 or 8 micrograms) and of the midbrain raphé nuclei (electrolytic 2 X 1.0 mA 10 sec) at 7 days postlesion on striatal levels of beta-phenylethylamine, DA, DOPAC, HVA, 5-HT and 5-HIAA and on hypothalamic levels of beta-phenylethylamine, DA, NA, 5-HT and 5-HIAA were investigated. In the presence of deprenyl (2 mg kg-1 2 hr SC), both electrolytic and 6-OHDA-induced dopamine-depleting lesions of the nigra but not 5-HT-depleting lesions of the raphé nuclei resulted in a marked decrease in the accumulation of beta-phenylethylamine. The marked reduction in accumulation of striatal beta-phenylethylamine in response to lesions of the substantia nigra indicates that the intraneuronal compartment is a major site of striatal beta-phenylethylamine synthesis. An equivalent decrease (approximately 40%) in the accumulation of 5-HT was observed following electrolytic lesions of the substantia nigra or raphé nuclei after administration of L-5-HTP (200 mg kg-1 hr IP). As L-5-HTP at the dose employed in this study is taken up non-selectively by both DA- and 5-HT-containing neurones the loss of L-AAD following nigral and raphé lesions was apparently equivalent. These results indicate that depletion of beta-phenylethylamine may not be simply attributable to a general loss of L-AAD following lesions of monoamine-containing neurones and suggest either co-localisation of beta-phenylethylamine and DA or the existence of distinct beta-phenylethylamine-containing neurones.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3096499     DOI: 10.1016/0361-9230(86)90214-5

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  8 in total

1.  Trace amines depress D(2)-autoreceptor-mediated responses on midbrain dopaminergic cells.

Authors:  Ada Ledonne; Mauro Federici; Michela Giustizieri; Mauro Pessia; Paola Imbrici; Mark J Millan; Giorgio Bernardi; Nicola B Mercuri
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

2.  Decreased beta-phenylethylamine in CSF in Parkinson's disease.

Authors:  G Zhou; H Shoji; S Yamada; T Matsuishi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-12       Impact factor: 10.154

3.  The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions.

Authors:  E Scarr; D M Wingerchuk; A V Juorio; I A Paterson
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

4.  Phenylalanine in the caudate nucleus of dopamine depleted rats.

Authors:  P R Paetsch; A J Greenshaw; A V Juorio
Journal:  Neurochem Res       Date:  1993-09       Impact factor: 3.996

Review 5.  Trace amine-associated receptor 1-Family archetype or iconoclast?

Authors:  David K Grandy
Journal:  Pharmacol Ther       Date:  2007-07-17       Impact factor: 12.310

6.  Reciprocal changes in striatal dopamine and beta-phenylethylamine induced by reserpine in the presence of monoamine oxidase inhibitors.

Authors:  A V Juorio; A J Greenshaw; T B Wishart
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-12       Impact factor: 3.000

7.  The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine.

Authors:  M D Berry; E Scarr; M Y Zhu; I A Paterson; A V Juorio
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

8.  Plasma Biomarkers for Monitoring Brain Pathophysiology in FMR1 Premutation Carriers.

Authors:  Cecilia Giulivi; Eleonora Napoli; Flora Tassone; Julian Halmai; Randi Hagerman
Journal:  Front Mol Neurosci       Date:  2016-08-12       Impact factor: 5.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.